Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.75 |
| ▸ | KMO | O15229 | 2/20 | 0.61 |
| ▸ | RXRA | P19793 | 2/20 | 0.59 |
| ▸ | RXRB | P28702 | 2/20 | 0.59 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.57 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149289 | 0.87 | KMO (0.63) | ERN1KMORXRARXRBAKR1C2 | |
| SCHEMBL12767057 | 0.86 | ERN1 (1.00) | ERN1RXRARXRB | |
| SCHEMBL28257767 | 0.85 | KMO (0.66) | ERN1KMORXRARXRBCA12 | |
| SCHEMBL13137668 | 0.84 | KMO (0.63) | ERN1KMORXRARXRBAKR1C2 | |
| SCHEMBL10012987 | 0.82 | KMO (0.79) | ERN1KMORXRARXRBCA12 | |
| SCHEMBL16429234 | 0.82 | KMO (0.87) | ERN1KMORXRARXRBCA12 | |
| SCHEMBL71238 | 0.82 | KMO (0.86) | ERN1KMORXRARXRBCA12 | |
| SCHEMBL29904709 | 0.82 | KMO (0.86) | ERN1KMORXRARXRBCA12 | |
| SCHEMBL30725957 | 0.82 | KMO (0.86) | ERN1KMORXRARXRBCA12 | |
| SCHEMBL410738 | 0.81 | KMO (0.66) | ERN1KMORXRARXRBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2325651-B1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20140134753-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140134753-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140134753-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-05-15 | — | — | US | disclosed |
| US-8653119-B2 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653119-B2 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653119-B2 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120288568-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | REVISION THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120202885-A1 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | REVISION THERAPEUTICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8168663-B2 | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-7214695-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE | 2007-04-05 | — | — | US | disclosed |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE | 2007-04-05 | — | — | US | disclosed |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE | 2007-04-05 | — | — | US | disclosed |
| US-20070015827-A1 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | SYTERA, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| WO-2007008821-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | SIRION THERAPEUTICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20060135460-A1 | Methods, assays and compositions for treating retinol-related diseases | SYTERA, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2006063128-A2 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INSTITUTE, THE | 2006-03-16 | — | — | US | disclosed |
| US-20040152140-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288568-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | RBP1, RBP4, ALDH1A2 | ERN1 1905/4885KMO 4463/4885RXRA 23/4885 |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | TTR, TTPA, PRNP | ERN1 1119/4885KMO 4375/4885RXRA 3616/4885 |
| US-20060135460-A1 | Methods, assays and compositions for treating retinol-related diseases | RBP1, RBP4, TTR | ERN1 1268/4885KMO 4765/4885RXRA 51/4885 |
| US-20070015827-A1 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | RBP1, RBP4, ALDH1A2 | ERN1 1905/4885KMO 4463/4885RXRA 23/4885 |
| US-20120202885-A1 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | RBP1, RBP4, TTR | ERN1 1268/4885KMO 4765/4885RXRA 51/4885 |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | TTR, TTPA, PRNP | ERN1 697/4885KMO 4198/4885RXRA 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.